abstract BACKGROUND: Vitamin D deficiency may represent a modifiable risk factor to improve outcome in severe illness. The efficacy of high-dose regimens in rapid normalization of vitamin D levels is uncertain.
The evidence for vitamin D in calcium homeostasis, cardiovascular and respiratory health, inflammation, and innate immunity has led to questions about whether deficiency might represent a modifiable risk factor in the prevention of or recovery from acute and critical illness. A large body of observational literature from adult ICU and cardiovascular populations has documented high vitamin D deficiency (VDD) rates and association between blood 25-hydroxyvitamin D (25[OH]D) and organ dysfunction, health resource utilization, and mortality. More recently, pediatric observational studies have supported these findings in similar populations, including patients with asthma, ICU patients, and postsurgical patients with congenital heart disease. [1] [2] [3] [4] [5] Normalization of vitamin D status has the potential to speed recovery and improve outcomes in multiple acutely unwell pediatric populations. Most of the guidelines and clinical practice surrounding vitamin D dosing involves a daily intake of ,1000 IU. 6,7 Because these standard dosing strategies target healthy children and require months to restore normal levels, they are not applicable to the acute and critical care settings. Although other regimens that involve the administration of higher doses have been reported, there remains concern about both inadequate dosing and excessive doses leading to toxicity. 8, 9 In the adult ICU setting, pilot trials of loading dose therapy have been completed, with results from a large trial evaluating clinical benefit completed but unpublished. [10] [11] [12] No PICU studies have been completed, with the results of the first phase III evaluating clinical benefit published in the fall of 2014.
To inform clinical practice and future trials, we performed a systematic review with the goal of identifying all published pediatric trials that reported on the administration of high-dose vitamin D ($1000 IU). The objectives of this review were as follows: (1) to assess the ability of different dosing regimens to normalize vitamin D status, (2) to determine study characteristics that influence post-study drug 25(OH)D levels, (3) to determine what highdose regimens are associated with vitamin D-related adverse events, and (4) to use the findings to recommend a dosing regimen for clinical practice and future clinical trials in pediatric acute and critical care settings.
METHODS
Study objectives and protocol were determined a priori (PROSPERO protocol registration number: CRD42013006677) and reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. 13 
Eligibility Criteria
Studies were eligible for inclusion in the systematic review if they met all of the following criteria: (1) an uncontrolled, controlled, or randomized controlled trial (RCT) conducted in neonates, infants, children, or adolescents; (2) the study administered at least 1 dose of cholecalciferol (vitamin D 3 ) or ergocalciferol (vitamin D 2 ) $1000 IU; and (3) the study evaluated the effects of drug administration on 25(OH)D status. Studies were excluded if the study population was exclusively premature or of low birth weight, had a genetic problem related to vitamin D metabolism, or was pregnant. Furthermore, studies were excluded if they prescribed UV exposure, gave vitamin D as part of a food without precisely controlling quantity, or administered vitamin D with another vitamin or drug (without a control arm).
Identification of Studies
Medline ; week 2, January 10th), Embase (1974 Embase ( -2014 ; week 3, January 17th), and the Cochrane Central Register of Controlled Trials (December 2013) were searched by using the Ovid interface. The Medline search strategy was developed by a librarian experienced in systematic review searching (M.S.) and peer-reviewed by another librarian (Lorie Kloda, MLIS, PhD), using the PRESS (Peer Review of Electronic Search Strategies) standard. 14 The Medline search was then adapted for the other databases. No date, language, or study design limits were applied. We searched conference abstracts from 2010 to 2013 through Scopus. The search strategies are presented in the Supplemental Information. The initial search was conducted on April 30, 2013, and updated on January 21, 2014. We also conducted a gray literature search by reviewing ongoing trials registered with clinicaltrials.gov, the citations of all eligible articles, and 24 systematic reviews of vitamin D in children.
Unless otherwise noted, 2 of the study authors independently reviewed the citations sequentially through 3 sets of screening questions to determine eligibility (Supplemental Table 6 ). Level 1 screening was performed by using Mendeley (Mendeley Desktop, version 1.10.3), and those citations that could not be excluded were uploaded to DistillerSR (Evidence Partners, Inc, Ottawa, Canada) for level 2 and 3 screening. The full text of all potentially eligible citations was independently appraised by at least 2 of 3 reviewers (K.I., K.O., J.D.M.). Conflicts between reviewers were resolved through discussion, with a third author available to resolve disagreement (M.S.). The eligibility of articles not in English, French, or Spanish was determined by a single author after written translation or with the assistance of a translator. managed by using REDCap (Research Electronic Data Capture) hosted at the Children's Hospital of Eastern Ontario. 15 Vitamin D or calcium data values that were only published graphically were extracted from figures by using DigitizeIt software (http://www.digitizeit.de/; Germany). During the data collection process, 18 authors were contacted to clarify or request additional 25(OH)D study data, 5 of whom responded. Study quality was described by using the Cochrane risk of bias assessment tool. 16 
Data Analysis and Reporting
Summary statistics and data from eligible studies and independent arms were described as text, through tables and figures. Clinical heterogeneity between studies was assessed by using information on population (age, disease status, baseline vitamin D), dosing regimen (dose, frequency, form, route), and measurement features (time, assay type). Regimens were considered intermittent if they provided a vitamin D dose in excess of 40 000 IU as a single administration (or divided over 2 days) or were repeated with a frequency .1 month. Methodologic heterogeneity was evaluated by using information collected on study type (single arm, RCT, controlled non-randomized trial) and the Cochrane risk of bias tool. For specific dosing regimens, 25(OH)D response was presented using figures (Sigma plot, version 12.3) and the success of each dosing regimen was defined as achieving a group 25(OH)D average .75 nmol/L. Given significant heterogeneity in post-25(OH)D administration levels, we performed random-effects metaregression to evaluate the contributions of specific study-level population, dosing, and methodologic characteristics. This analysis included study arms reporting a group 25(OH)D level between 1 and 13 weeks after drug initiation and for which an accurate cumulative dose could be calculated. An assessment of heterogeneity and meta-analysis was performed by using Comprehensive Meta-Analysis (version 2) with metaregression performed using the PROC MIXED function in SAS (version 9.3; SAS Institute, Cary, NC). Analysis used group mean or median 25(OH)D levels and within-study variance with the use of provided or calculated SEs. 17, 18 For age, if the median or mean was not provided we used the midpoint of the age range as an approximation. 19 Initially, singlevariable random-effects metaregression was performed and potentially significant variables were then tested in a multivariable metaregression analysis. A potential interaction was sought between cumulative dose and age, and an interaction term was included in the regression analysis to control for and evaluate for how timing from a single or divided loading dose influences the 25OHD levels influenced the level. No new variables were to be added to the multivariable model once the ratio of variables to eligible 25(OH)D measurements exceeded 10:1. The final multivariate model was used to predict group 25(OH)D levels after 4 loading doses in 4 age groups of VDD children with disease (Table 5) . Figure 1 shows the flow of studies through the identification and review process. A total of 2453 unique records were identified for screening. Of the 367 full-text citations that remained after initial screening, 256 articles describing clinical trials were identified. Of these, 88 full-text publications 8,20-107 and 10 conference abstracts (Supplemental Table 7 ) met all population, dosing, and 25(OH)D outcome-related eligibility criteria. The flow of eligible articles and study arms is presented in Supplemental Figure 5 . The 88 fulltext articles reported on 96 eligible study populations and included 199 different arms. Of these 199 arms, 3 were ineligible due to UV exposure (n = 2) or administration of active vitamin D (n = 1). Of the remaining arms, 62 involved the administration of no vitamin D (eg, placebo) or a dose ,1000 IU. Of the 134 highdose arms, 22% (n = 29) and 78% (n = 105) were from uncontrolled and controlled studies, respectively. Tables 1 and 2 relevant clinical and methodologic characteristics of the eligible high-dose arms. Of the eligible high-dose study arms, 73% involved administration of vitamin D to healthy children (49%), children with rickets (16%), or pediatric populations with subclinical VDD (8%). Populations of children with "other" disease states (eg, HIV, arthritis, seizures) accounted for 19% of the study arms (Supplemental Table 8 ). As shown in Table 1 , studies included children from all age ranges, with neonates being evaluated in 15% (n = 20) and adolescents in 50% (n = 67) of high-dose study arms. Vitamin D dosing regimens evaluating intermittent loading therapy accounted for 46% (n = 62) of the eligible study arms, with daily regimens representing 38% (n = 51). A minority of the eligible high-dose arms (14%; n = 19) described a dosing regimen that varied depending on factors including baseline 25(OH)D, weight, or age. The number of participants in each arm ranged from 5 to 233, with a median size of 27 (interquartile range: 13-40).
RESULTS

Search Strategy
Patient Populations
At least 1 measure of average post-study drug group absolute 25(OH)D (or change) was available from all but 1 of the high-dose study arms. Of the 134 high-dose arms, 35% (n = 48) and 76% (n = 106) measured 25(OH)D within 1 and 3 months of study drug initiation. Supplemental Tables 9-16 112 evaluated response to an age-based loading regimen (,3 years:150 000 IU; 3-12 years: 300 000 IU; .12 years: 600 000 IU) among 40 children; ∼6 weeks after treatment, the group average increased from 27 to 93 nmol/L, with at least 1 participant exceeding 300 nmol/L.
Factors Associated With Post-Study Drug 25(OH)D Levels
Significant heterogeneity in post-study drug 25(OH)D was evident, with group average levels ranging from 30 to 399 nmol/L, and a calculated I 2 value of 99. Singlevariable random-effects metaregression identified 8 variables as statistically significant, with 2 additional variables approaching significance (Table 3) . Multivariate random-effects meta-regression performed by using data available from 102 independent arms
FIGURE 1
Flowchart of study selection based on inclusion and exclusion criteria. The stages of a systematic selection scheme include identification, screening, eligibility, and final included studies. a Numbers will not total 168 because studies could be excluded for multiple reasons.
identified 7 variables that were independently statistically significant in either the main effects or through an interaction ( The most common definition was 250 nmol/L (n = 6) and another 2 used definitions of 374 and 375 nmol/L.
Adverse Event Analysis
There were 39 study arms that reported on high-dose ($1000 IU) vitamin D regimens that provided hypercalcemia data within 3 months of drug initiation. Information on relevant population, dosing, and adverse events measurements is provided in Supplemental Tables 17  and 18 . There were 23 study arms who received intermittent, weekly, or daily high-dose loading regimens. Significant heterogeneity in hypercalcemia rates was calculated (I 2 = 61%; see Fig 4) . Randomeffects meta-analysis identified a statistically significant difference in hypercalcemia rates between accepted daily dosing (2.6%; CI: 1.1%-5.9%) and intermittent, weekly, and daily high-dose loading regimens (7.6%; CI: 4.1%-13.7%; P = .041). Further analysis identified higher hypercalcemia rates for the arms $400 000 IU (23.8%; CI: 16.3%-33.3%) when compared with doses #300 000 IU (4.2%; CI: 2.0%-8.8%; P = .0001). Subgroup analysis using 25(OH)D data revealed that hypercalcemia was more likely among studies with average group levels .200 nmol/L compared with those with levels ,200 nmol/L (3.9% vs 19.6%; P = .006). Pooled hypercalcemia rates were similar for groups with levels ,100 nmol/L and those with levels between 100 and 200 nmol/L. Further subgroup analysis by age was not possible due to the limited number of loading regimens administering doses .300 000 IU.
For hypercalciuria (29 study arms; Supplemental Tables 19-21) , 
FIGURE 4
Forest plot of hypercalcemia rates by dosing regimen. Random-effects meta-analysis was used to calculate pooled hypercalcemia rates and 95% CIs for all high-dose vitamin D regimens ($1000 IU) and regimen subgroups. Point estimates are shown as the vertical lines in the boxes, and 95% CIs are represented by the edge of the boxes. The y-axis describes the various subgroup analyses.
10 000 IU/kg. A review of published variable high-dose regimens identified 7 independent pediatric populations with 25(OH)D measurements after the administration of 10 000 IU/kg intramuscular vitamin D. These studies suggest that intramuscular dosing might rapidly normalize vitamin D status, although the lack of measurements within the first month and paucity of enteral studies prevent definitive conclusions. Nevertheless, results from the intramuscular studies are relevant because many acute and hospitalized patients suffer significant malabsorption and/or are not able to take food and medication enterally. 123, 124 The need for pediatric studies evaluating 10 000 IU/kg using the enteral route is reinforced by evidence from adult studies that show significant differences in short-term response between enteral and intramuscular routes. 125, 126 The current review also examined whether high-dose loading regimens were associated with vitamin D-related adverse events and toxicity. 
